Endovia Health Sciences (EDVA) Net Income towards Common Stockholders Growth (5y) (2017 - 2026)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Net Income towards Common Stockholders Growth (5y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.06 Bn | 133.21 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.96 Bn | 78.97 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.74 Bn | 1.37 Bn |
| 4 | Moderna | 57.22 Bn | 52.08 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.59 Bn | 44.59 Bn | - |
| 6 | BeOne Medicines | 40.43 Bn | 35.33 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.17 Bn | 27.34 Bn | - |
| 9 | Insmed | 27.60 Bn | 26.43 Bn | 358.27 Mn |
| 10 | Endovia Health Sciences | 821,701.01 | 578,999.01 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.08% |
| Mar 31, 2026 | 13.62% |
| Dec 31, 2025 | 36.56% |
| Sep 30, 2025 | -34.05% |
| Jun 30, 2025 | -86.07% |
| Mar 31, 2025 | 1.01% |
| Dec 31, 2024 | -61.67% |
| Sep 30, 2024 | -34.63% |
| Jun 30, 2024 | -89.43% |
| Mar 31, 2024 | -143.70% |
| Dec 31, 2023 | -233.56% |
| Sep 30, 2023 | -308.35% |
| Jun 30, 2023 | -143.07% |
| Mar 31, 2023 | -185.11% |
| Dec 31, 2022 | -116.02% |
| Sep 30, 2022 | -171.41% |
| Jun 30, 2022 | -213.12% |
| Mar 31, 2022 | -149.57% |
| Dec 31, 2021 | -228.97% |
| Sep 30, 2021 | -300.35% |